3SBio Inc
HKEX:1530
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.69
35.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
3SBio Inc
Operating Income
3SBio Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
3SBio Inc
HKEX:1530
|
Operating Income
¥2.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Operating Income
-¥4.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Operating Income
¥1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Operating Income
-¥675.3m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Operating Income
-¥119m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Operating Income
-¥212.1m
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
3SBio Inc
Glance View
3SBio Inc., founded in 1993, is a prominent player in the biopharmaceutical landscape of China. Driven by a mission to improve human health quality through biopharmaceutical innovation, the company has cultivated a robust portfolio of products, primarily focusing on three key therapeutic areas: oncology, nephrology, and autoimmune diseases. At the core of 3SBio's operations is its strong emphasis on research and development, with several state-of-the-art facilities where it continuously explores advancements in biological medicines. These efforts have positioned the company as a leader in the production of recombinant proteins and antibodies, which are essential in treating chronic and life-threatening conditions. 3SBio derives its revenue through a well-integrated business model that spans drug development, manufacturing, and commercialization. This model allows the company not only to generate income from its diverse product offerings but also to leverage strategic partnerships and licensing agreements, both locally and internationally. Their flagship products, such as EPIAO, a recombinant human erythropoietin used to treat anemia associated with chronic kidney disease, and TPIAO, a thrombopoietin receptor agonist used in the management of idiopathic thrombocytopenic purpura, are among the top revenue drivers. By maintaining a strong pipeline of both innovative and biosimilar products, 3SBio ensures sustained profitability and growth, meeting the ever-evolving demands of healthcare systems and patients worldwide. Amidst the competitive and rapidly evolving biotech industry, 3SBio stands out with its commitment to quality and innovation, anchored by a strategic vision to expand its influence beyond traditional boundaries.
See Also
What is 3SBio Inc's Operating Income?
Operating Income
2.5B
CNY
Based on the financial report for Jun 30, 2025, 3SBio Inc's Operating Income amounts to 2.5B CNY.
What is 3SBio Inc's Operating Income growth rate?
Operating Income CAGR 5Y
9%
Over the last year, the Operating Income growth was 11%. The average annual Operating Income growth rates for 3SBio Inc have been 13% over the past three years , 9% over the past five years .